UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 321

Sortiert nach

sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH

Proceedings of the National Academy of Sciences - PNAS, 2019-05, Vol.116 (22), p.11057-11062

2019

Volltextzugriff (PDF)

Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate

Gastroenterology (New York, N.Y. 1943), 2013-12, Vol.145 (6), p.1334-1346.e11

2013

Volltextzugriff (PDF)

Two Randomized Trials of Linaclotide for Chronic Constipation

The New England journal of medicine, 2011-08, Vol.365 (6), p.527-536

2011

Volltextzugriff (PDF)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

The American journal of gastroenterology, 2018-01, Vol.113 (1), p.105-114

2018

Volltextzugriff (PDF)

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial

PloS one, 2015-07, Vol.10 (7), p.e0134349-e0134349

2015

Volltextzugriff (PDF)

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

European journal of pharmacology, 2010-12, Vol.649 (1), p.328-335

2010

Volltextzugriff (PDF)

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

Journal of neuroinflammation, 2021-09, Vol.18 (1), p.213-213, Article 213

2021

Volltextzugriff (PDF)

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases

Frontiers in pharmacology, 2021-05, Vol.12, p.656561-656561

2021

Volltextzugriff (PDF)

Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease

Frontiers in pharmacology, 2020-04, Vol.11, p.419-419

2020

Volltextzugriff (PDF)

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain

Frontiers in molecular neuroscience, 2014-04, Vol.7, p.31-31

2014

Volltextzugriff (PDF)

A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics

The FASEB journal, 2003-07, Vol.17 (10), p.1298-1300

2003

Volltextzugriff (PDF)

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

The American journal of gastroenterology, 2012-11, Vol.107 (11), p.1702-1712

2012

Volltextzugriff (PDF)

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats

Pharmacology research & perspectives, 2020-04, Vol.8 (2), p.e00579-n/a

2020

Volltextzugriff (PDF)

Differential Bile Acid Detection in Refractory GERD Patient Saliva Using a Simple and Sensitive Liquid Chromatography Tandem Mass Spectrometry Approach

Journal of clinical gastroenterology, 2022-03, Vol.56 (3), p.218

2022

Volltextzugriff (PDF)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

The American journal of gastroenterology, 2012-11, Vol.107 (11), p.1714-1724

2012

Volltextzugriff (PDF)

Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure

American journal of physiology. Renal physiology, 2020-01, Vol.318 (1), p.F148-F159

2020

Volltextzugriff (PDF)

Peroxynitrite Decomposition Catalysts: Therapeutics for Peroxynitrite-Mediated Pathology

Proceedings of the National Academy of Sciences - PNAS, 1998-03, Vol.95 (5), p.2659-2663

1998

Volltextzugriff (PDF)

Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

Gastroenterology (New York, N.Y. 1943), 2010-12, Vol.139 (6), p.1877-1886.e2

2010

Volltextzugriff (PDF)

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease

The Journal of pharmacology and experimental therapeutics, 2018-06, Vol.365 (3), p.664

2018

Volltextzugriff (PDF)

Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial

Clinical journal of the American Society of Nephrology, 2021, Vol.16 (1), p.59-69

2021

Volltextzugriff (PDF)

IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial

Gastroenterology (New York, N.Y. 1943), 2020-06, Vol.158 (8), p.2093-2103

2020

Volltextzugriff (PDF)

Efficacy of Linaclotide for Patients With Chronic Constipation

Gastroenterology (New York, N.Y. 1943), 2010-03, Vol.138 (3), p.886-895.e1

2010

Volltextzugriff (PDF)

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

The Journal of pharmacology and experimental therapeutics, 2013-01, Vol.344 (1), p.196

2013

Volltextzugriff (PDF)

Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions

Journal of gastroenterology and hepatology, 2018-05, Vol.33 (5), p.980-989

2018

Volltextzugriff (PDF)

Effects of a Gastric-Retentive Extended-Release Bile Acid Sequestrant on Esophageal Erosions in Patients With Persistent GERD: Exploratory Analysis From a Phase 2B Study of IW-3718: 393

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S227-S228

2018

Volltextzugriff (PDF)

1 – 25 von 321

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(286)

Publikationsform

Sprache

Englisch
(321)
Japanisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(222)
Life Sciences & Biomedicine
(187)
Humans
(118)
Animals
(110)
Biological And Medical Sciences
(97)
Male
(91)
Medical Sciences
(65)
Female
(64)
Rats
(53)
Middle Aged
(47)
Aged
(39)
Pharmacology & Pharmacy
(38)
Fundamental And Applied Biological Sciences. Psychology
(37)
Adult
(34)
Gastroenterology And Hepatology
(33)
Infectious Diseases
(27)
Burkholderia Pseudomallei
(24)
Molecular Sequence Data
(22)
Pharmacology. Drug Treatments
(22)
Rats, Sprague-Dawley
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH

Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate

Two Randomized Trials of Linaclotide for Chronic Constipation

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases

Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain

A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats

Differential Bile Acid Detection in Refractory GERD Patient Saliva Using a Simple and Sensitive Liquid Chromatography Tandem Mass Spectrometry Approach

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure

Peroxynitrite Decomposition Catalysts: Therapeutics for Peroxynitrite-Mediated Pathology

Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease

Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial

IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial

Efficacy of Linaclotide for Patients With Chronic Constipation

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation

Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions

Effects of a Gastric-Retentive Extended-Release Bile Acid Sequestrant on Esophageal Erosions in Patients With Persistent GERD: Exploratory Analysis From a Phase 2B Study of IW-3718: 393

Suchergebnisse filtern